Trobix plans to use its GoTraP™ and ActiSense™ platform technologies to springboard a pipeline of products for treating human antibacterial resistant infections.
Our initial pipeline is focused on developing human therapeutic products that abolish carbapenem and ESBL resistance in gut Enterobacteriaceae.
Trobix Bio lead product, TBX101, targets the large population of patients carrying antibiotic resistant bacteria in their gut, that spread deadly infections in hospitals and medical centers. TBX101 is being developed as an orally available pill that will re-sensitize the gut microbiome of these patients to antibiotics. This is an innovative approach to microbiome management, offering for the first time a preventative treatment that holds the potential to dramatically reduce hospital morbidity and mortality caused by such pathogens.
Trobix Bio plans to explore other potential opportunities using its platform technology to develop new antibacterial products to serve various sectors in the fight against antimicrobial resistance.
Such sectors include:
Non-antibiotic products such as disinfectants and hand sanitizers that can kill and sensitize antibiotics in hospital and community settings for safer environmental control.
Reducing the overuse of antibiotics by developing non-antibiotic treatments for various animal infectious diseases.
Developing non-antibiotic based products to remove food poisoning causing bacteria in poultry and meat.
We welcome collaborations to advance the development of novel products.
For further information, please contact firstname.lastname@example.org